Caresyntax is a leader in the fast growing data-assisted surgery category. The investment will accelerate the adoption and development of Caresyntax's AI-enabled surgical software and fund strategic M&A activity.

surgical.ai participated in the funding round with a combined eight figure investment alongside several leading strategic and financial investors including Symbiotic Capital, MTIP AG, Pictet Alternative Advisors, Aescuvest, PFM Health Sciences, BlackRock, Optum Ventures, Relyens, and others.

Caresyntax is on a mission to make surgery smarter and safer by converging AI-powered software, devices, and clinical services to improve patient outcomes. Their vendor-neutral, precision surgery platform delivers actionable insights to improve patient outcomes. Their proprietary software and AI platform is capturing and analyzing large volumes of video, audio, images, device data, clinical and operational data in and around the OR. The software and automation platform can be used by the care team live, during a procedure, and accessed by those outside the operating room via the platform's secured dedicated cloud and telehealth links. The Caresyntax platform provides meta-data insights and real-world evidence (RWE) that help surgeons and teams to improve their care, hospital administrators to use resources more efficiently, and medical device companies to advance products. It also supports insurance companies to understand and control risks, as well as enable contracts on a value-based model.